Kindred Biosciences Stock Forecast, Price & News

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

Is Kindred Biosciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Kindred Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View analyst ratings for Kindred Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Kindred Biosciences?

Wall Street analysts have given Kindred Biosciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Kindred Biosciences.

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.
View Kindred Biosciences' earnings history.

How has Kindred Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KIN shares have increased by 14.3% and is now trading at $9.25.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KIN?

5 Wall Street analysts have issued 1-year price targets for Kindred Biosciences' shares. Their forecasts range from $9.25 to $15.25. On average, they anticipate Kindred Biosciences' share price to reach $10.75 in the next year. This suggests a possible upside of 16.2% from the stock's current price.
View analysts' price targets for Kindred Biosciences or view top-rated stocks among Wall Street analysts.

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:

• Richard H. Chin, President, Chief Executive Officer & Director (LinkedIn Profile)
• Wendy Wee, Secretary, Chief Financial & Accounting Officer
• Hangjun Zhan, Chief Scientific Officer
• Russell Radefeld, VP-Information Technology & Digital Marketing
• Jay Peterson, Senior Director-Biomanufacturing

Who are some of Kindred Biosciences' key competitors?

Some companies that are related to Kindred Biosciences include MorphoSys (MOR), Amneal Pharmaceuticals (AMRX), IVERIC bio (ISEE), Global Blood Therapeutics (GBT), Centessa Pharmaceuticals (CNTA), Prelude Therapeutics (PRLD), Dicerna Pharmaceuticals (DRNA), Kadmon (KDMN), uniQure (QURE), PureTech Health (PRTC), Day One Biopharmaceuticals (DAWN), Travere Therapeutics (TVTX), CytoDyn (CYDY), Supernus Pharmaceuticals (SUPN) and Nurix Therapeutics (NRIX).
View all of KIN's competitors.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Magnetar Financial LLC (7.55%), Millennium Management LLC (6.05%), Vanguard Group Inc. (4.16%), Point72 Asset Management L.P. (3.56%), Renaissance Technologies LLC (2.91%) and Dimensional Fund Advisors LP (2.73%). Company insiders that own Kindred Biosciences stock include Denise Bevers, Park West Asset Management Llc and Richard Chin.
View institutional ownership trends for Kindred Biosciences.

Which major investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., State Street Corp, Northern Trust Corp, Silverback Asset Management LLC, Geode Capital Management LLC, General American Investors Co. Inc., and Vanguard Group Inc.. Company insiders that have sold Kindred Biosciences company stock in the last year include Denise Bevers, Park West Asset Management Llc, and Richard Chin.
View insider buying and selling activity for Kindred Biosciences or view top insider-selling stocks.

Which major investors are buying Kindred Biosciences stock?

KIN stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Millennium Management LLC, Gabelli Funds LLC, Morgan Stanley, Morgan Stanley, SG Americas Securities LLC, Balyasny Asset Management LLC, and Glazer Capital LLC.
View insider buying and selling activity for Kindred Biosciences or or view top insider-buying stocks.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $9.25.

How much money does Kindred Biosciences make?

Kindred Biosciences has a market capitalization of $420.52 million and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Kindred Biosciences have?

Kindred Biosciences employs 63 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is kindredbio.com.

Where are Kindred Biosciences' headquarters?

Kindred Biosciences is headquartered at 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at (650) 701-7901 or via email at [email protected].